Abstract
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by an excessive production of auto-antibodies against double-stranded DNA, nucleosomes, ribonucleoproteins and other nuclear components. Accumulation of self-reactive antibodies leads to immune complex deposition in blood vessels, activation of macrophages and complement, inflammation and subsequent tissue damage in several organs, such as the heart, kidneys, lungs and central nervous system. Although significant progress has been made in the past 30 years of research, no effective specific treatments are currently available. The course of this disease remains unpredictable and patients diagnosed with SLE face long-term treatments with the subsequent economic, social and health burden. From the immunological perspective, SLE is a genetic- and environment-controlled disease that involves almost every constituent of the immune system, including both innate and adaptive immunity. Therefore, several immune cell types and molecules could be susceptible for intervention and modulation to develop more effective and specific treatments. More importantly, such therapies are likely not to induce complete immunosuppression and show reduced side effects on patients. In this article we discuss recent work in the field of SLE pathogenesis with a focus on data that provide clues for therapy design and new treatments.
Keywords: Autoimmune diseases, dendritic cells, immune tolerance, immunotherapy, lupus, T cells
Current Gene Therapy
Title: Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Volume: 11 Issue: 6
Author(s): Carolina Llanos, Leandro J. Carreno, Miguel A. Gutierrez, Claudia A. Riedel, Sergio H. Jacobelli and Alexis M. Kalergis
Affiliation:
Keywords: Autoimmune diseases, dendritic cells, immune tolerance, immunotherapy, lupus, T cells
Abstract: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by an excessive production of auto-antibodies against double-stranded DNA, nucleosomes, ribonucleoproteins and other nuclear components. Accumulation of self-reactive antibodies leads to immune complex deposition in blood vessels, activation of macrophages and complement, inflammation and subsequent tissue damage in several organs, such as the heart, kidneys, lungs and central nervous system. Although significant progress has been made in the past 30 years of research, no effective specific treatments are currently available. The course of this disease remains unpredictable and patients diagnosed with SLE face long-term treatments with the subsequent economic, social and health burden. From the immunological perspective, SLE is a genetic- and environment-controlled disease that involves almost every constituent of the immune system, including both innate and adaptive immunity. Therefore, several immune cell types and molecules could be susceptible for intervention and modulation to develop more effective and specific treatments. More importantly, such therapies are likely not to induce complete immunosuppression and show reduced side effects on patients. In this article we discuss recent work in the field of SLE pathogenesis with a focus on data that provide clues for therapy design and new treatments.
Export Options
About this article
Cite this article as:
Llanos Carolina, J. Carreno Leandro, A. Gutierrez Miguel, A. Riedel Claudia, H. Jacobelli Sergio and M. Kalergis Alexis, Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus, Current Gene Therapy 2011; 11 (6) . https://dx.doi.org/10.2174/156652311798192806
DOI https://dx.doi.org/10.2174/156652311798192806 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyreactive Antibodies in Anti-HIV-1 Responses
Current Molecular Medicine Mediterrranean Diet and Health Biological Importance of Olive Oil
Current Pharmaceutical Design Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents
Current Molecular Medicine Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Current Pharmaceutical Design ‘Toll’ Gates for Future Immunotherapy
Current Pharmaceutical Design Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome
Current Medicinal Chemistry Peptide Arrays for the Analysis of Antibody Epitope Recognition Patterns
Mini-Reviews in Organic Chemistry Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets The Role of Autophagy in Rheumatic Disease
Current Drug Targets Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Current Pharmaceutical Design The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets The Interleukin-17/Interleukin-22 Innate Axis in the Gut as a New Drug Target in Allergic-Inflammatory and Autoimmune Diseases. A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Toll-Like Receptor Signaling Mechanisms Involved in Dendritic Cell Activation: Potential Therapeutic Control of T Cell Polarization
Current Pharmaceutical Design Systemic Immunomodulation of Autoimmune Disease Using MHC-Derived Recombinant TCR Ligands
Current Drug Targets - Inflammation & Allergy Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sjögren’s Syndrome
Current Rheumatology Reviews